Sharma, P. et al. Immune checkpoint therapy—current perspectives and future directions. Cell 186, 1652–1669 (2023).

Article  PubMed  CAS  Google Scholar 

Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838–857 (2021).

Article  PubMed  CAS  Google Scholar 

Woodcock, J. & LaVange, L. M. Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med. 377, 62–70 (2017).

Article  PubMed  CAS  Google Scholar 

Bhatt, D. L. & Mehta, C. Adaptive designs for clinical trials. N. Engl. J. Med. 375, 65–74 (2016).

Article  PubMed  Google Scholar 

Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).

Article  PubMed  CAS  Google Scholar 

Carthon, B. C. et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16, 2861–2871 (2010).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hodi, F. S. et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl Acad. Sci. USA 105, 3005–3010 (2008).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205–214 (2015).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).

Article  PubMed  CAS  Google Scholar 

Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).

Article  PubMed  CAS  Google Scholar 

Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24–34 (2022).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chauvin, J. M. & Zarour, H. M. TIGIT in cancer immunotherapy. J. Immunother. Cancer 8, e000957 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Acharya, N., Sabatos-Peyton, C. & Anderson, A. C. Tim-3 finds its place in the cancer immunotherapy landscape. J. Immunother. Cancer 8, e000911 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Maruhashi, T. et al. LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII. Nat. Immunol. 19, 1415–1426 (2018).

Article  PubMed  CAS  Google Scholar 

Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36, 471–482 (2019).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lam, N., Lee, Y. & Farber, D. L. A guide to adaptive immune memory. Nat. Rev. Immunol. 24, 810–829 (2024).

Article  PubMed  CAS  Google Scholar 

Pittet, M. J., Di Pilato, M., Garris, C. & Mempel, T. R. Dendritic cells as shepherds of T cell immunity in cancer. Immunity 56, 2218–2230 (2023).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer–immunity cycle. Immunity 39, 1–10 (2013).

Article  PubMed  Google Scholar 

Giles, J. R., Globig, A. M., Kaech, S. M. & Wherry, E. J. CD8+ T cells in the cancer-immunity cycle. Immunity 56, 2231–2253 (2023).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schenkel, J. M. & Pauken, K. E. Localization, tissue biology and T cell state—implications for cancer immunotherapy. Nat. Rev. Immunol. 23, 807–823 (2023).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Livingstone, E. et al. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Lancet 400, 1117–1129 (2022).

Article  PubMed  CAS  Google Scholar 

O’Malley, D. M. et al. Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study. J. Clin. Oncol. 40, 762–771 (2022).

Article  PubMed  Google Scholar 

Olson, D. J. et al. Pembrolizumab plus ipilimumab following anti-PD-1/L1 failure in melanoma. J. Clin. Oncol. 39, 2647–2655 (2021).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lee, J. B., Kim, H. R. & Ha, S. J. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. Immune Netw. 22, e2 (2022).

Article  PubMed  PubMed Central  Google Scholar 

O’Reilly, E. M. et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 5, 1431–1438 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Omuro, A. et al. Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neurooncol. Adv. 4, vdac025 (2022).

PubMed  PubMed Central  Google Scholar 

Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 6, 1003–1010 (2020).

Article  PubMed  Google Scholar 

Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Amaria, R. N. et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 611, 155–160 (2022).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mullard, A. Roche’s anti-TIGIT drug suffers a phase III cancer setback. Nat. Rev. Drug Discov. 21, 327 (2022).

PubMed  Google Scholar 

Cho, B. C. et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 23, 781–792 (2022).

Article  PubMed  CAS  Google Scholar 

Rousseau, A., Parisi, C. & Barlesi, F. Anti-TIGIT therapies for solid tumors: a systematic review. ESMO Open 8, 101184 (2023).